Biotech and life sciences commercial strategy differs from conventional B2B or B2C marketing in fundamental ways. The customers are physicians, hospital systems, payers, and patients - each with different decision-making criteria, regulatory constraints, and communication requirements. The timeline from development to commercialization spans years, not quarters. And the FDA's promotional guidelines create a compliance layer that most marketing professionals are not trained to navigate.
Mark builds commercial strategies for biotech companies that respect these constraints while building the market awareness, KOL networks, and pre-commercial positioning that reduce launch risk and accelerate revenue once approval is secured.
Build disease state awareness, establish KOL relationships, generate clinical evidence content, and lay the commercial foundation before FDA approval. Companies that invest in pre-launch market development consistently outperform those that wait until approval to begin commercial activities.
Identify, map, and engage key opinion leaders at academic medical centers, community practices, and professional societies. Advisory boards, speaker programs, peer-reviewed publication support, and the relationship management that puts your asset at the top of the prescribing mindset.
Health economics and outcomes research (HEOR) positioning, formulary access strategy, and the value story that moves payers from tier 3 to tier 1 coverage. The commercial strategy that ignores payers fails at reimbursement regardless of physician demand.
Patient advocacy organization partnerships, DTC awareness campaigns where appropriate, and the patient journey marketing that drives diagnosis rates and treatment-seeking behavior for conditions with high undiagnosed populations.
For diagnostics and medical devices, different reimbursement codes (CPT/HCPCS), different buyer personas (lab directors, hospital supply chain, surgeons), and different adoption curves require a specialized GTM framework separate from therapeutic drug launches.
Build the narrative that attracts partnership and acquisition interest from Big Pharma, strategic investors, and licensing opportunities. The commercial positioning story needs to work for capital markets as well as clinical markets.
FDA regulations governing pharmaceutical and device promotion (21 CFR Parts 202 and 203, plus OPDP guidance) create real constraints that biotech marketing must operate within. Key principles:
Mark works with biotech companies to build marketing programs that maximize commercial impact within these constraints, and coordinates with medical-legal-regulatory review processes to ensure materials are compliant before deployment.
Broader healthcare marketing covering providers, payers, and health services companies.
For digital health and health tech companies with software-driven go-to-market models.
Build the commercial strategy framework before you need it - pre-launch market development starts here.